TVGN earnings analysis
What we found in TVGN's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The provided excerpt does not include the financial statements or MD&A, so revenue, margins, EPS, cash flow, balance-sheet trends, and segment performance cannot be assessed. The most material update is the company’s failure to meet Nasdaq’s $50 million and $15 million market-value requirements, with compliance deadlines of October 13 and October 14, 2026. Disclosure controls remained ineffective due to a previously reported material weakness, while no material legal proceedings were pending.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- No Material Legal Proceedings
- The company reported no material legal proceedings pending as of the filing date, August 14, 2026.
- No Insider Trading Arrangements
- No directors or officers adopted or terminated a Rule 10b5-1 or non-Rule 10b5-1 trading arrangement during the three months ended June 30, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Nasdaq Listing Compliance Risk
- Nasdaq notified the company on April 16 and April 17, 2026 that it failed the $50 million minimum market value of listed securities requirement and the $15 million minimum market value of publicly held shares requirement. The compliance deadlines are October 13, 2026 and October 14, 2026, respectively, after a 180-calendar-day remediation period.
- Material Control Weakness Persists
- Disclosure controls and procedures were concluded to be ineffective at the reasonable assurance level as of June 30, 2026 because of a material weakness in internal control over financial reporting previously disclosed in the 2025 Form 10-K; the filing states there were no changes during the quarter that materially affected controls.
What they said about what is next.
The provided filing excerpt contains no quantitative revenue or EPS outlook; outlook appears deferred to the earnings release or call.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 15, 2026
- Tevogen Bio Holdings Inc. continues to struggle financially as it reports a net loss of $5.4 million for the first quarter of 2026, a notable reduction from a $10.4 million loss in the same period of 2025, primarily due…
- 10-K · April 30, 2026
- Tevogen Bio Holdings Inc. reported significant challenges in its financial position and operational outcomes over the past year. The company faced compliance issues with Nasdaq regarding market value thresholds and…
- 10-K · March 31, 2026
- Tevogen is a clinical-stage immunotherapy company developing ExacTcell-based allogeneic CD8+ T cell therapies, led by TVGN 489 (COVID-19 / Long COVID). The filing emphasizes Phase 1 safety/persistence data (no…
- 10-Q · November 14, 2025
- Tevogen reported no revenue and a modest sequential improvement in its quarterly operating loss: Q3 net loss was $5,726,812 (net loss per share $0.03) versus $5,884,223 in Q3 2024. Liquidity was bolstered by equity and…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing TVGN makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever